|
US9829494B2
(en)
|
2005-12-01 |
2017-11-28 |
Adrenomed Ag |
Methods of treatment using ADM antibodies
|
|
ES2828739T3
(es)
|
2006-04-07 |
2021-05-27 |
Aerpio Pharmaceuticals Inc |
Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
AR081361A1
(es)
*
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
DK2643349T3
(da)
*
|
2010-11-26 |
2019-11-25 |
Molecular Partners Ag |
Designede repeat-proteiner, der binder til serumalbumin
|
|
EP2702069A4
(en)
|
2011-04-29 |
2015-04-29 |
Janssen Biotech Inc |
IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
US20130095065A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for Treating Vascular Leak Syndrome and Cancer
|
|
EP2780370B1
(en)
|
2011-11-16 |
2019-09-25 |
AdrenoMed AG |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
|
|
MY178654A
(en)
|
2011-11-16 |
2020-10-20 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
|
|
EP4086283A1
(en)
|
2011-11-16 |
2022-11-09 |
AdrenoMed AG |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
|
KR102249078B1
(ko)
|
2011-11-16 |
2021-05-10 |
아드레노메드 아게 |
요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
|
|
SG11201402362VA
(en)
|
2011-11-16 |
2014-06-27 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
|
HRP20190122T1
(hr)
|
2011-11-16 |
2019-03-08 |
Adrenomed Ag |
Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
HUE046134T2
(hu)
*
|
2012-05-07 |
2020-02-28 |
Allergan Inc |
Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
|
|
AU2013269594C1
(en)
|
2012-06-01 |
2020-12-17 |
Novartis Ag |
Syringe
|
|
EP2867360B1
(en)
*
|
2012-06-28 |
2019-05-08 |
Molecular Partners AG |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
|
AU2013100071C4
(en)
*
|
2012-07-03 |
2013-05-02 |
Novartis Ag |
Device
|
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
|
AU2012101678B4
(en)
*
|
2012-07-03 |
2013-01-24 |
Novartis Ag |
Use of device
|
|
JP2015528454A
(ja)
*
|
2012-08-28 |
2015-09-28 |
ノバルティス アーゲー |
眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用
|
|
RU2679913C2
(ru)
|
2012-10-02 |
2019-02-14 |
Сфинготек Гмбх |
Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
CA2897327A1
(en)
|
2013-01-08 |
2014-07-17 |
Sphingotec Gmbh |
Fasting levels of growth hormone as a predictive marker of cardiovascular risk
|
|
WO2014131694A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2014151725A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Allergan, Inc. |
Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
|
|
SG10201800309SA
(en)
|
2013-03-20 |
2018-02-27 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
US11453708B2
(en)
|
2013-05-31 |
2022-09-27 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to hepatocyte growth factor
|
|
EP3010525A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
US20160129080A1
(en)
|
2013-06-20 |
2016-05-12 |
Aaron Osborne |
Treatment of polypoidal chroidal vasculopathy
|
|
US20160130321A1
(en)
|
2013-06-20 |
2016-05-12 |
Gabriela Burian |
Use of a vegf antagonist in treating macular edema
|
|
RU2676303C2
(ru)
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
EP3019526A1
(en)
|
2013-07-11 |
2016-05-18 |
Novartis AG |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
SG11201510315TA
(en)
|
2013-07-12 |
2016-01-28 |
Ophthotech Corp |
Methods for treating or preventing ophthalmological conditions
|
|
PL3065761T3
(pl)
*
|
2013-11-05 |
2020-05-18 |
Allergan, Inc. |
Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
EP3002589A1
(en)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
A method for stratifying a female subject for hormone replacement therapy
|
|
WO2016156596A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Molecular Partners Ag |
Designed ankyrin repeat domains with binding specificity for serum albumin
|
|
WO2016170023A1
(en)
|
2015-04-24 |
2016-10-27 |
Sphingotec Gmbh |
A method for predicting the risk of incidence of chronic kidney disease
|
|
TWI799366B
(zh)
*
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
EP3377151A1
(en)
|
2015-11-18 |
2018-09-26 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
|
MX382662B
(es)
|
2015-11-18 |
2025-03-11 |
Sio2 Medical Products Inc |
Envase farmacéutico para formulaciones oftálmicas.
|
|
RU2734958C2
(ru)
|
2015-11-18 |
2020-10-26 |
Формикон Аг |
Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
|
|
EP3407868A1
(en)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Liquid formulation of a vegf antagonist
|
|
WO2017148904A1
(en)
|
2016-02-29 |
2017-09-08 |
Franz Grus |
Predictive markers useful in the treatment of wet age-related macular degeneration
|
|
DE112017002105T5
(de)
|
2016-04-21 |
2019-04-25 |
Sphingotec Therapeutics Gmbh |
Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren
|
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
|
CN109716136B
(zh)
|
2016-07-08 |
2023-09-22 |
斯弗因高泰克有限公司 |
肾上腺髓质素用于评估急性心力衰竭患者的充血
|
|
SG11201900464TA
(en)
|
2016-07-20 |
2019-02-27 |
Aerpio Therapeutics Inc |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
MX377424B
(es)
|
2016-09-22 |
2025-03-10 |
Molecular Partners Ag |
Proteinas de union recombinantes y sus usos
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
RU2021135712A
(ru)
|
2016-12-16 |
2021-12-30 |
Адреномед Аг |
АНТИТЕЛО ПРОТИВ АДРЕНОМЕДУЛЛИНА (ADM), ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM не-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ ПРИ ВМЕШАТЕЛЬСТВЕ И ТЕРАПИИ ГИПЕРЕМИИ У ПАЦИЕНТА
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200237997A1
(en)
|
2017-05-24 |
2020-07-30 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
US20200182885A1
(en)
|
2017-05-30 |
2020-06-11 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfuntion
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
SG11202001420VA
(en)
|
2017-08-18 |
2020-03-30 |
Cambridge Entpr Ltd |
Modular binding proteins
|
|
RS66415B1
(sr)
|
2017-09-25 |
2025-02-28 |
Adrenomed Ag |
Anti-adrenomedulin (adm) – vezujući entitet za upotrebu u terapiji ili prevenciji simptoma bolesti
|
|
JP2021500548A
(ja)
|
2017-10-18 |
2021-01-07 |
アドレノメト アクチェンゲゼルシャフト |
抗アドレノメデュリン(adm)結合剤での処置下での治療モニタリング
|
|
RU2020115377A
(ru)
|
2017-10-24 |
2021-11-25 |
Сфинготек Гмбх |
Селенопротеин p для прогнозирования первого сердечно-сосудистого явления
|
|
JP7424972B2
(ja)
|
2017-10-25 |
2024-01-30 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特定のdpp3エピトープに指向され、そしてそれに結合するdpp3バインダー、ならびに酸化ストレスに関連する疾患/急性病態の予防または治療におけるその使用
|
|
US20210302440A1
(en)
|
2018-02-08 |
2021-09-30 |
Sphingotec Gmbh |
Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
EP3856245A4
(en)
|
2018-09-24 |
2022-10-26 |
EyePoint Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
|
|
SG11202105176QA
(en)
|
2018-12-20 |
2021-06-29 |
Sphingotec Gmbh |
Selenoprotein p in heart failure
|
|
CN113557031A
(zh)
|
2018-12-21 |
2021-10-26 |
4Teen4制药有限公司 |
使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
|
|
EP3980443A1
(en)
|
2019-06-04 |
2022-04-13 |
Molecular Partners AG |
Multispecific proteins
|
|
BR112022001417A2
(pt)
|
2019-08-15 |
2022-05-24 |
Sphingotec Gmbh |
Método para diagnóstico ou monitoramento de função renal ou diagnóstico de disfunção renal em pacientes pediátricos
|
|
MX2022002432A
(es)
|
2019-08-30 |
2022-06-02 |
4TEEN4 Pharmaceuticals GmbH |
Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques.
|
|
WO2021116462A1
(en)
|
2019-12-11 |
2021-06-17 |
Molecular Partners Ag |
Designed ankyrin repeat domains with altered surface residues
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
JP2023515985A
(ja)
|
2020-02-27 |
2023-04-17 |
アドレノメト アクチェンゲゼルシャフト |
ショック状態の患者の治療において使用するための抗アドレノメデュリン(adm)結合剤
|
|
JP2023515042A
(ja)
|
2020-02-27 |
2023-04-12 |
アドレノメト アクチェンゲゼルシャフト |
ショックの治療若しくは予防において使用するための抗アドレノメデュリン(ADM)抗体若しくは抗ADM抗体フラグメント又は抗ADM非Ig足場
|
|
AU2021228207A1
(en)
|
2020-02-27 |
2022-10-20 |
4TEEN4 Pharmaceuticals GmbH |
DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
BR112022017277A2
(pt)
|
2020-03-16 |
2022-10-18 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 em pacientes infectados com coronavírus
|
|
KR20220154743A
(ko)
|
2020-03-16 |
2022-11-22 |
아드레노메드 아게 |
코로나 바이러스에 감염된 환자에서 프로-아드레노메둘린 또는 그의 단편, 및 아드레노메둘린에 대한 결합제에 의한 치료
|
|
TW202208404A
(zh)
|
2020-05-06 |
2022-03-01 |
瑞士商分子組合公司 |
新穎錨蛋白重複結合蛋白質及其用途
|
|
CN115768786A
(zh)
|
2020-05-14 |
2023-03-07 |
分子合作伙伴股份公司 |
多特异性蛋白质
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
CA3202358A1
(en)
|
2020-12-16 |
2022-06-23 |
Andreas BOSSHART |
Novel slow-release prodrugs
|
|
US20240150475A1
(en)
|
2021-03-09 |
2024-05-09 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
CA3211248A1
(en)
|
2021-03-09 |
2022-09-15 |
Nina RESCHKE |
Novel darpin based cd33 engagers
|
|
JP2024509904A
(ja)
|
2021-03-09 |
2024-03-05 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規なDARPinに基づく多重特異性T細胞エンゲージャ
|
|
WO2022190008A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Protease cleavable prodrugs
|
|
EP4329734A4
(en)
|
2021-04-26 |
2025-04-02 |
Celanese EVA Performance Polymers LLC |
Implantable device for the delayed release of a macromolecular drug compound
|
|
JP2024526081A
(ja)
|
2021-06-18 |
2024-07-17 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
敗血症及び敗血症性ショックを予測する方法
|
|
EP4363859A1
(en)
|
2021-06-29 |
2024-05-08 |
berYsol GmbH |
Composite biomarker for the identification of selenium deficiency in a bodily fluid
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
AU2022413461A1
(en)
|
2021-12-14 |
2024-06-06 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
|
US20250304671A1
(en)
|
2022-03-15 |
2025-10-02 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|
|
EP4562035A1
(en)
|
2022-07-29 |
2025-06-04 |
AdrenoMed AG |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
WO2024023368A1
(en)
|
2022-07-29 |
2024-02-01 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
|
CN119731200A
(zh)
|
2022-08-01 |
2025-03-28 |
分子合作伙伴股份公司 |
经电荷修饰设计的重复结构域及其用途
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
CN120359042A
(zh)
|
2022-12-15 |
2025-07-22 |
4Teen4制药有限公司 |
改善危重病患者肺功能的dpp3抑制剂
|
|
WO2024179981A1
(en)
|
2023-02-27 |
2024-09-06 |
Molecular Partners Ag |
Darpins for use in reducing renal accumulation of drugs
|
|
CN120731367A
(zh)
|
2023-03-17 |
2025-09-30 |
Pam治疗诊断有限公司 |
肽基甘氨酸α-酰胺化单加氧酶(PAM)的测定方法及其诊断用途
|
|
WO2024200862A1
(en)
|
2023-03-29 |
2024-10-03 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
|
|
WO2025068313A1
(en)
|
2023-09-25 |
2025-04-03 |
Sphingotec Gmbh |
A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|